Biomea Fusion Inc. (BMEA), a clinical-stage biopharmaceutical company, expects to present data from its COVALENT-103 trial on December 9, 2024.
COVALENT-103 is a Phase I trial evaluating the company's drug candidate BMF-500 in adult patients with relapsed or refractory acute leukemia with FMS-like tyrosine kinase 3 (FLT3) wild-type and FLT3 mutations.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com